Charming Shoppes Newswire

Charming Shoppes Newswire

Comprehensive Real-Time News Feed for Charming Shoppes.

Results 1 - 20 of 325 in Charming Shoppes

  1. Coherus BioSciences (CHRS) Given Media Impact Rating of 0.16Read the original story w/Photo

    Sunday Apr 22 | Daily Political

    News articles about Coherus BioSciences have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time.

    Comment?

  2. Coherus BioSciences (CHRS) Lowered to "Strong Sell" at ValuEngineRead the original story w/Photo

    Sunday Apr 22 | Daily Political

    A number of other analysts have also recently commented on the company. Zacks Investment Research cut Coherus BioSciences from a buy rating to a hold rating in a research report on Tuesday, January 9th.

    Comment?

  3. Geode Capital Management LLC Buys 9,621 Shares of Coherus BioSciencesRead the original story w/Photo

    Sunday Apr 22 | IntersportsWire

    Geode Capital Management LLC raised its stake in shares of Coherus BioSciences by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The firm owned 389,013 shares of the biotechnology company's stock after purchasing an additional 9,621 shares during the period.

    Comment?

  4. Deutsche Bank AG Has $3.15 Million Holdings in Coherus BioSciencesRead the original story w/Photo

    Sunday Apr 22 | AmericanBankingNews.com

    Deutsche Bank AG raised its stake in Coherus BioSciences by 346.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 357,954 shares of the biotechnology company's stock after acquiring an additional 277,788 shares during the quarter.

    Comment?

  5. Coherus BioSciences (CHRS) Downgraded to Strong Sell at ValuEngineRead the original story w/Photo

    Saturday Apr 21 | AmericanBankingNews.com

    Other analysts have also issued research reports about the company. BidaskClub lowered Coherus BioSciences from a "hold" rating to a "sell" rating in a research note on Saturday, February 3rd.

    Comment?

  6. Coherus BioSciences (CHRS) Expected to Post Earnings of -$0.84 Per ShareRead the original story w/Photo

    Saturday Apr 21 | AmericanBankingNews.com

    Analysts expect that Coherus BioSciences will report earnings per share of for the current fiscal quarter, according to Zacks . Zero analysts have provided estimates for Coherus BioSciences' earnings.

    Comment?

  7. Teachers Advisors LLC Buys 12,619 Shares of Coherus BioSciencesRead the original story w/Photo

    Saturday Apr 21 | Daily Political

    Teachers Advisors LLC increased its stake in Coherus BioSciences by 14.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 97,494 shares of the biotechnology company's stock after acquiring an additional 12,619 shares during the quarter.

    Comment?

  8. Coherus BioSciences Announces New Employment Inducement GrantsRead the original story

    Thursday Apr 19 | Customer Interaction Solutions

    Coherus BioSciences, Inc. , today announced that effective April 19, 2018, the compensation committee of the company's board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company's common stock with a per share exercise price of $12.05, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2016 under Rule 5635 of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

    Comment?

  9. Wells Fargo & Company MN Raises Position in Coherus BioSciencesRead the original story w/Photo

    Monday Apr 16 | AmericanBankingNews.com

    Wells Fargo & Company MN increased its position in shares of Coherus BioSciences by 38.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 212,790 shares of the biotechnology company's stock after acquiring an additional 58,764 shares during the period.

    Comment?

  10. Millennium Management LLC Increases Holdings in Coherus BioSciencesRead the original story w/Photo

    Monday Apr 16 | AmericanBankingNews.com

    Millennium Management LLC raised its stake in Coherus BioSciences by 543.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 695,286 shares of the biotechnology company's stock after buying an additional 587,248 shares during the quarter.

    Comment?

  11. Coherus BioSciences (CHRS) Upgraded at ValuEngineRead the original story w/Photo

    Sunday Apr 15 | IntersportsWire

    Other research analysts have also issued reports about the company. BidaskClub raised Coherus BioSciences from a sell rating to a hold rating in a report on Thursday, December 21st.

    Comment?

  12. BlackRock Inc. Sells 79,323 Shares of Coherus BioSciencesRead the original story w/Photo

    Saturday Apr 14 | Daily Political

    BlackRock Inc. lessened its stake in Coherus BioSciences by 2.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,198,726 shares of the biotechnology company's stock after selling 79,323 shares during the quarter.

    Comment?

  13. Coherus BioSciences (CHRS) Upgraded by ValuEngine to SellRead the original story w/Photo

    Friday Apr 13 | Daily Political

    CHRS has been the topic of a number of other reports. Citigroup boosted their target price on Coherus BioSciences from $23.00 to $25.00 and gave the stock a buy rating in a research report on Friday, March 9th.

    Comment?

  14. Coherus BioSciences (CHRS) Shares Bought by Goldman Sachs Group Inc.Read the original story w/Photo

    Friday Apr 13 | AmericanBankingNews.com

    Goldman Sachs Group Inc. lifted its position in Coherus BioSciences by 131.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 339,480 shares of the biotechnology company's stock after buying an additional 192,883 shares during the quarter.

    Comment?

  15. Coherus BioSciences (CHRS) Rating Increased to Sell at ValuEngineRead the original story w/Photo

    Thursday Apr 12 | AmericanBankingNews.com

    CHRS has been the subject of several other research reports. Zacks Investment Research cut shares of Coherus BioSciences from a "buy" rating to a "hold" rating in a report on Tuesday, January 9th.

    Comment?

  16. Coherus BioSciences (CHRS) Shares Sold by Rhumbline AdvisersRead the original story w/Photo

    Tuesday Apr 10 | Daily Political

    Rhumbline Advisers reduced its stake in shares of Coherus BioSciences by 15.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 36,197 shares of the biotechnology company's stock after selling 6,595 shares during the quarter.

    Comment?

  17. Coherus BioSciences (CHRS) Expected to Announce Earnings of -$0.84 Per ShareRead the original story w/Photo

    Monday Apr 9 | Daily Political

    Equities analysts predict that Coherus BioSciences will post earnings per share of for the current quarter, according to Zacks Investment Research . Zero analysts have issued estimates for Coherus BioSciences' earnings.

    Comment?

  18. Tiaa Cref Investment Management LLC Has $9.18 Million Stake in Coherus BioSciencesRead the original story w/Photo

    Monday Apr 9 | AmericanBankingNews.com

    TIAA CREF Investment Management LLC lifted its stake in shares of Coherus BioSciences by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,042,995 shares of the biotechnology company's stock after buying an additional 12,313 shares during the quarter.

    Comment?

  19. Coherus BioSciences (CHRS) Downgraded to Sell at Zacks Investment ResearchRead the original story w/Photo

    Saturday Apr 7 | AmericanBankingNews.com

    According to Zacks, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients.

    Comment?

  20. Coherus Biosciences Inc (CHRS) Receives Average Recommendation of "Buy" from AnalystsRead the original story w/Photo

    Thursday Apr 5 | AmericanBankingNews.com

    Shares of Coherus Biosciences Inc have earned a consensus recommendation of "Buy" from the eleven analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company.

    Comment?